Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in noncirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)

Authors
Category Primary study
JournalJournal of Hepatology
Year 2017
This article has no abstract
Epistemonikos ID: fcb33042c2d6ed66f89f229f752b9d29a828dd01
First added on: Feb 09, 2025